Physician profile
Daniel Ivan Chang
NPI 1922727353
$4,951.35
in general payments reported to CMS, 2019-2025
14 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,904 · 2024: $1,757 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,924 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,924.08 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $935.32 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $721.70 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $556.83 | 2023-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $551.30 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $508.90 | 2023-2024 | Ingrezza |
| Abbvie INC. | $465.79 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $323.54 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $287.97 | 2023-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Novo Nordisk INC | $143.97 | 2023-2024 | Wegovy |
| Vanda Pharmaceuticals INC. | $138.61 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $124.42 | 2025 | Auvelity |
| Alpha Cognition USA, INC. | $77.82 | 2025 | Zunveyl |
| Bausch Health US, LLC | $71.79 | 2023-2024 | Aplenzin |
| Lundbeck LLC | $43.39 | 2024-2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.